Lilly Reports Omvoh Achieved Multiple Treatment Goals Simultaneously At One Year In IBD Studies
In LUCENT-2, more than one in four (27.7%) Omvoh-treated patients with ulcerative colitis achieved comprehensive disease control, a novel composite outcome defined by simultaneous symptomatic, endoscopic and histologic
Lilly's new IBD medicine Omvoh helped about 28% of patients feel better and heal completely. When a medicine works on multiple problems at once, it shows the company has a strong treatment option.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.